Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

No reversion in vigabatrin-associated visual field defects.

I Nousiainen1, M Mäntyjärvi, R Kälviäinen

  • 1Department of Neurology, Kuopio University Hospital, Finland. Iiris.Nousiainen@uku.fi

Neurology
|November 28, 2001
PubMed
Summary

Vigabatrin treatment for epilepsy can cause visual field defects. Long-term follow-up showed no improvement or worsening of these visual field defects after stopping vigabatrin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proceedings from ERN EpiCARE "BEYOND SEIZURES" meeting, Aalesund, Norway, May the 27th. Advancing holistic care for rare and complex epilepsies in adults.

Epilepsy & behavior : E&B·2026
Same author

Declining trend in valproate use in Finland among females of childbearing age in 2012-2016 - a nationwide registry-based outpatient study.

European journal of neurology·2018
Same author

Cognitive Adverse Effects of Antiepileptic Drugs : Incidence, Mechanisms and Therapeutic Implications.

CNS drugs·2015
Same author

Sensorimotor, visual, and auditory cortical atrophy in Unverricht-Lundborg disease mapped with cortical thickness analysis.

AJNR. American journal of neuroradiology·2012
Same author

Non-vision adverse events with vigabatrin therapy.

Acta neurologica Scandinavica. Supplementum·2011
Same author

Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS).

European journal of neurology·2010

Area of Science:

  • Neurology
  • Ophthalmology
  • Pharmacology

Background:

  • Vigabatrin is an antiepileptic drug used for partial epilepsy.
  • Visual field defects are a known potential side effect of vigabatrin therapy.
  • Long-term effects of vigabatrin on vision require further investigation.

Purpose of the Study:

  • To evaluate the prevalence of vigabatrin-associated visual field defects.
  • To identify risk factors for these defects.
  • To assess the long-term outcome of visual field defects after vigabatrin discontinuation.

Main Methods:

  • Sixty adult patients with partial epilepsy on vigabatrin therapy were included.
  • Repeated kinetic Goldmann perimetry was used for visual field assessment.
  • A follow-up examination was conducted after a mean of 15 months.

Related Experiment Videos

Main Results:

  • Visual field defects were observed in patients treated with vigabatrin.
  • Neither improvement nor progression of visual field constriction was noted during follow-up.
  • Discontinuation of vigabatrin therapy did not lead to reversion or progression of defects.

Conclusions:

  • Vigabatrin-associated visual field defects may be persistent.
  • No significant changes in visual fields were observed after discontinuing vigabatrin.
  • Further research is needed to understand the mechanisms and long-term implications.